ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The "ALARM" study.Cancer medicine · 2024Pooled it
- Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer.International journal of radiation oncology, biology, physics · 2026Article
- Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells.Scientific reports · 2026Article
- Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses.bioRxiv : the preprint server for biology · 2026Article
- Novel Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Beyond EGFR and Checkpoint Blockade.Biomedicines · 2025Review
- DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications.Nature reviews. Drug discovery · 2025Review
- PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications.Frontiers in oncology · 2025Review
- Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.International journal of molecular sciences · 2024Review
- Development and Validation of a Pathomics Model Using Machine Learning to Predict CXCL8 Expression and Prognosis in Head and Neck Cancer.Clinical and experimental otorhinolaryngology · 2024Article
- Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma.Clinical and translational radiation oncology · 2024Article
- DNA as the main target in radiotherapy-a historical overview from first isolation to anti-tumour immune response.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Review
- Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Review
- Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1.Clinical and translational radiation oncology · 2023Article
- Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study.Clinical and translational radiation oncology · 2023Article
- DNA Damage Response Mechanisms in Head and Neck Cancer: Significant Implications for Therapy and Survival.International journal of molecular sciences · 2023Review
- Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- PARP inhibitors combined with radiotherapy: are we ready?Frontiers in pharmacology · 2023Review
- Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.Frontiers in oncology · 2023Review
- BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Sana D KaramDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Krishna ReddyDepartment of Radiation Oncology, University of Toledo, Toledo, Ohio.
Patrick J BlatchfordDepartment of Biostatistics, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Tim WaxweilerDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Alicia M DeLouizeDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Ayman OweidaDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Hilary SomersetDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Carrie MarshallDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Christian YoungDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Kurtis D DaviesDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Madeleine KaneDepartment of Medicine, Division of Medical Oncology, Anschutz Medical Campus, Aurora, Colorado.
Aik Choo TanDepartment of Medicine, Division of Medical Oncology, Anschutz Medical Campus, Aurora, Colorado.
Xiao Jing WangDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Antonio JimenoDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Dara L AisnerDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Daniel W BowlesDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
David RabenDepartment of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. david.raben@ucdenver.edu.
University of Colorado Anschutz Medical Campus · USVA Eastern Colorado Health Care System · USUniversity of Toledo · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MPaul Calabresis Award in Clinical Oncology ResearchK12CA086913 · NCI · UNIVERSITY OF COLORADO DENVER · PI VIRGINIA F. BORGES, Jill E Slansky · 2000 to 2026
$17.8MNCI NIH HHS K12 CA086913NCI NIH HHS P30 CA046934
Abstract
PubMed holds no abstract for this paper.
Indexed as
Radiotherapy, Intensity-ModulatedSmokersAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCetuximabCombined Modality TherapyDNA Mutational AnalysisFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPhthalazinesBiomarkers, TumorCetuximabolaparibPhthalazinesPiperazines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.